<?xml version="1.1" encoding="utf-8"?>
<rdf:RDF xmlns:OMEXlib="http://omex-library.org/"
   xmlns:bqbiol="http://biomodels.net/biology-qualifiers/"
   xmlns:bqmodel="http://biomodels.net/model-qualifiers/"
   xmlns:dc="http://purl.org/dc/terms/"
   xmlns:foaf="http://xmlns.com/foaf/0.1/"
   xmlns:local="http://omex-library.org/NewOmex.omex/NewModel.rdf#"
   xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
  <rdf:Description rdf:about="http://omex-library.org/BIOMD0000000521.omex">
    <bqmodel:isDescribedBy rdf:resource="local:00001"/>
    <ns1:keyword xmlns:ns1="http://prismstandard.org/namespaces/basic/2.0/">Biomodels</ns1:keyword>
    <ns2:description xmlns:ns2="http://purl.org/dc/elements/1.1/">&lt;body xmlns="http://www.w3.org/1999/xhtml"&gt;
  &lt;div class="dc:title"&gt;Ribba2012 - Low-grade gliomas, tumour growth inhibition model&lt;/div&gt;
  &lt;div class="dc:description"&gt;
    &lt;p&gt;Using longitudinal mean tumour diameter (MTD) data, this model describe the size evolution of low-grade glioma (LGG) in patients treated with chemotherapy or radiotherapy.&lt;/p&gt;
  &lt;/div&gt;
  &lt;div class="dc:bibliographicCitation"&gt;
    &lt;p&gt;This model is described in the article:&lt;/p&gt;
    &lt;div class="bibo:title"&gt;
      &lt;a href="http://identifiers.org/pubmed/22761472" title="Access to this publication"&gt;A tumour growth inhibition model for low-grade glioma treated with chemotherapy or radiotherapy&lt;/a&gt;
    &lt;/div&gt;
    &lt;div class="bibo:authorList"&gt;Ribba B, Kaloshi G, Peyre M, Ricard D, Calvez V, Tod M, Cajavec-Bernard B, Idbaih A, Psimaras D, Dainese L, Pallud J, Cartalat-Carel S, Delattre JY, Honnorat J, Grenier E, Ducray F.&lt;/div&gt;
    &lt;div class="bibo:Journal"&gt;Clin. Cancer Res. 2012 Sep; 18(18): 5071-5080&lt;/div&gt;
    &lt;p&gt;Abstract:&lt;/p&gt;
    &lt;div class="bibo:abstract"&gt;
      &lt;p&gt;PURPOSE: To develop a tumor growth inhibition model for adult diffuse low-grade gliomas (LGG) able to describe tumor size evolution in patients treated with chemotherapy or radiotherapy.&lt;/p&gt;
      &lt;p&gt;EXPERIMENTAL DESIGN: Using longitudinal mean tumor diameter (MTD) data from 21 patients treated with first-line procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea, and vincristine (PCV) chemotherapy, we formulated a model consisting of a system of differential equations, incorporating tumor-specific and treatment-related parameters that reflect the response of proliferative and quiescent tumor tissue to treatment. The model was then applied to the analysis of longitudinal tumor size data in 24 patients treated with first-line temozolomide (TMZ) chemotherapy and in 25 patients treated with first-line radiotherapy.&lt;/p&gt;
      &lt;p&gt;RESULTS: The model successfully described the MTD dynamics of LGG before, during, and after PCV chemotherapy. Using the same model structure, we were also able to successfully describe the MTD dynamics in LGG patients treated with TMZ chemotherapy or radiotherapy. Tumor-specific parameters were found to be consistent across the three treatment modalities. The model is robust to sensitivity analysis, and preliminary results suggest that it can predict treatment response on the basis of pretreatment tumor size data.&lt;/p&gt;
      &lt;p&gt;CONCLUSIONS: Using MTD data, we propose a tumor growth inhibition model able to describe LGG tumor size evolution in patients treated with chemotherapy or radiotherapy. In the future, this model might be used to predict treatment efficacy in LGG patients and could constitute a rational tool to conceive more effective chemotherapy schedules.&lt;/p&gt;
    &lt;/div&gt;
  &lt;/div&gt;
  &lt;div class="dc:publisher"&gt;
    &lt;p&gt;This model is hosted on        &lt;a href="http://www.ebi.ac.uk/biomodels/"&gt;BioModels Database&lt;/a&gt;
            and identified
by:        &lt;a href="http://identifiers.org/biomodels.db/BIOMD0000000521"&gt;BIOMD0000000521&lt;/a&gt;
            .        &lt;/p&gt;
    &lt;p&gt;To cite BioModels Database, please use:        &lt;a href="http://identifiers.org/pubmed/20587024" title="Latest BioModels Database publication"&gt;BioModels Database: An enhanced, curated and annotated resource
for published quantitative kinetic models&lt;/a&gt;
            .        &lt;/p&gt;
  &lt;/div&gt;
  &lt;div class="dc:license"&gt;
    &lt;p&gt;To the extent possible under law, all copyright and related or
neighbouring rights to this encoded model have been dedicated to the public
domain worldwide. Please refer to        &lt;a href="http://creativecommons.org/publicdomain/zero/1.0/" title="Access to: CC0 1.0 Universal (CC0 1.0), Public Domain Dedication"&gt;CC0 Public Domain
Dedication&lt;/a&gt;
            for more information.        &lt;/p&gt;
  &lt;/div&gt;
&lt;/body&gt;</ns2:description>
    <ns3:title xmlns:ns3="http://purl.org/dc/elements/1.1/">A tumor growth inhibition model for low-grade glioma treated with chemotherapy or radiotherapy</ns3:title>
  </rdf:Description>
  <rdf:Description rdf:about="local:00001">
    <ns4:identifier xmlns:ns4="http://purl.org/dc/elements/1.1/"
       rdf:resource="http://identifiers.org/doi/10.1158/1078-0432.CCR-12-0084"/>
    <ns5:label xmlns:ns5="http://www.w3.org/2000/01/rdf-schema#">Benjamin Ribba, Gentian Kaloshi, Mathieu Peyre, Damien Ricard, Vincent Calvez, Michel Tod, Branka Čajavec-Bernard, Ahmed Idbaih, Dimitri Psimaras, Linda Dainese, Johan Pallud, Stéphanie Cartalat-Carel, Jean-Yves Delattre, Jérôme Honnorat, Emmanuel Grenier &amp; François Ducray. A tumor growth inhibition model for low-grade glioma treated with chemotherapy or radiotherapy. Clinical Cancer Research 18, 18 (2012).</ns5:label>
  </rdf:Description>
</rdf:RDF>

